Translational Medicine,
R&D Oncology,
Translational Medicine, R&D Oncology
Melanie M. Frigault has not added Biography.
If you are Melanie M. Frigault and would like to personalize this page please email our Author Liaison for assistance.
Are companion diagnostics useful?
Clinical chemistry Jan, 2013 | Pubmed ID: 23193059
Is target validation all we need?
Current opinion in pharmacology Aug, 2014 | Pubmed ID: 25261632
The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.
Clinical cancer research : an official journal of the American Association for Cancer Research Jun, 2015 | Pubmed ID: 25779944
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology Sep, 2017 | Pubmed ID: 28644771
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 08, 2019 | Pubmed ID: 30952639
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Blood advances 05, 2019 | Pubmed ID: 31088809
Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Blood 04, 2020 | Pubmed ID: 31876911
Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia.
Cancer discovery 03, 2020 | Pubmed ID: 31915195
Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.
JAMA oncology 08, 2020 | Pubmed ID: 32469384
A Patient-Derived Cell Atlas Informs Precision Targeting of Glioblastoma.
Cell reports 07, 2020 | Pubmed ID: 32668248
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in -Amplified Gastric Cancer.
JCO precision oncology , 2020 | Pubmed ID: 32923890
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
Investigational new drugs Apr, 2021 | Pubmed ID: 33052556
JoVE 소개
Copyright © 2024 MyJoVE Corporation. 판권 소유